Should I Buy REPL? REPL 2026 Analysis

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.650

1 Day change

6.25%

52 Week Range

13.240

Analysis Updated At

2026/03/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Replimune Group Inc (REPL) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks immediate positive catalysts, and its financial performance remains weak. While there is some optimism from analysts and a potential FDA approval catalyst in April, the current technical indicators and pre-market price trend do not suggest a compelling entry point.

Technical Analysis

The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 61.55, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), signaling a downward trend. The stock is trading near its pivot level of 7.153, with resistance at 7.665 and support at 6.641. Pre-market price is down 1.99%, showing weakness.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market. However, implied volatility is high (271.56), suggesting significant uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

Analyst Piper Sandler raised the price target to $14 from $13, citing optimism around the FDA's acceptance of RP1's resubmission. Potential FDA approval in April could act as a major catalyst.

Neutral/Negative Catalysts

No significant insider or hedge fund activity. Pre-market price is down 1.99%, and the stock has a 60% chance of a slight decline (-0.68%) in the next day. Weak financial performance and no recent news or congress trading data.

Financial Performance

In Q3 2026, revenue remained at 0 with no YoY growth. Net income improved slightly by 6.92% YoY but remains negative at -$70.93 million. EPS dropped by 2.53% YoY to -0.77, indicating continued losses.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Piper Sandler maintains an Overweight rating and raised the price target to $14, reflecting optimism about RP1's FDA approval prospects. However, the approval decision still carries risk.

7 Analyst Rating

Wall Street analysts forecast REPL stock price to rise

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 7.200

Low

Averages

11.43

High

Current: 7.200

Low

Averages

11.43

High

Piper Sandler

Overweight

maintain

$13 -> $14

AI Analysis

2026-02-05

Reason

Piper Sandler

Price Target

$13 -> $14

AI Analysis

2026-02-05

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Replimune to $14 from $13 and keeps an Overweight rating on the shares following Q3 reporting and ahead of RP1's April 10 PDUFA date. Replimune has felt the full brunt of the impact of FDA turmoil and seemingly capricious decision-making in recent months, Piper notes. The firm understands that additional analyses addressing FDA's concern around the contribution of components in the single-arm IGNYTE trial played a key role in this apparent about-face, and finds these recently disclosed analyses compelling. While Piper acknowledges that RP1's approval decision still carries risk, it's the firm's sense that FDA wouldn't have accepted the resubmission with the intent of rejecting it a second time.

BMO Capital

Evan Seigerman

Underperform

Market Perform

upgrade

$2 -> $11

2025-11-03

Reason

BMO Capital

Evan Seigerman

Price Target

$2 -> $11

2025-11-03

upgrade

Underperform

Market Perform

Reason

BMO Capital analyst Evan Seigerman upgraded Replimune to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels "reflect appropriate risk" for the company's RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune's "productive" Type A meeting supports potential approval.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REPL

Unlock Now

REPL Should I Buy

REPL Should I Buy

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch